Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMATERAS-BC breast-conserving non-surgical strategy study in HER2-positive early breast cancer
jRCTs031190129Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of trastuzumab and pertuzumab in breast cancer (4 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 3-year distant metastasis-free survival rate. Started Nov 2019; status: active, not recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs031190129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190129.